The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML. [electronic resource]
Producer: 20190226Description: 2687-2701 p. digitalISSN:- 1476-5594
- Animals
- Antineoplastic Agents -- administration & dosage
- Cell Line, Tumor
- Cell Survival -- drug effects
- Cyclin-Dependent Kinase 9 -- antagonists & inhibitors
- Down-Regulation
- Drug Synergism
- Drug Therapy, Combination
- Enhancer Elements, Genetic -- drug effects
- Flavonoids -- administration & dosage
- Gene Expression Profiling -- methods
- Gene Expression Regulation, Neoplastic -- drug effects
- HL-60 Cells
- Humans
- Leukemia, Myeloid, Acute -- drug therapy
- Mice
- Piperidines -- administration & dosage
- Proteins -- antagonists & inhibitors
- Pyrazines -- administration & dosage
- RNA Polymerase II -- metabolism
- RNA-Binding Proteins -- genetics
- Transcription Factors
- Triazoles -- administration & dosage
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.